Chimpanzee News and Research

RSS

Development of multivalent next-generation vaccine strategy against ancestral SARS-CoV-2 and emerging variants

A recent study demonstrated that intranasal (i.n.) delivery of COVID-19 vaccine in murine models elicits greater immune responses against the wildtype SARS-CoV-2 and its variants.

14 Feb 2022

Unprecedented manufacturing strategy provides a template for equitable supply of vaccines

Today, as AstraZeneca reports 2 billion doses of the COVID-19 vaccine released for supply University of Oxford scientists explain how it has been possible to produce so much of the vaccine in less than a year, and the unprecedented strategy used to improve international equity of access.

16 Nov 2021

Immunity following COVID-19 vaccination and natural infection in India

The researchers evaluated immune response markers in a cross-section of people from the Indian state of West Bengal, including those vaccinated with either Covishield or Covaxin, the unvaccinated cohort, and the naturally infected.

11 Nov 2021

Humoral immunity following heterologous and homologous COVID-19 vaccination regimens

Researchers sought to analyze immune responses after homologous vaccinations or after heterologous Vector/mRNA vaccinations, with respect to anti-COVID-19 immune responses and the development of autoantibodies.

3 Nov 2021

Two-dose SARS-CoV-2 vaccine effectiveness against infection and hospitalization in Canada

Authors from varying Canadian institutes report on two-dose vaccine effectiveness against infection and hospitalization.

28 Oct 2021

Respiratory infections spread rapidly within mountain gorillas but not between neighboring groups

Coughs and colds spread quickly within wild mountain gorilla groups but appear less likely to spread between neighboring groups, a new study published in Scientific Reports shows.

8 Oct 2021

Joint commitment process of apes mirrors patterns similar to humans

When we're talking to another person, we probably wouldn't leave without saying goodbye; that would just be impolite.

11 Aug 2021

Next-generation COVID-19 vaccine provides robust immunity against SARS-CoV-2 in mice

Researchers in Canada have developed an adenoviral vector-based vaccine against coronavirus disease 2019 (COVID-19) that induced robust immune protection against the ancestral strain of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in mice.

20 Jul 2021

Initial SARS-CoV-2 vaccination response may predict BNT162b2 booster response, but not AZD1222

A new study finds that the antibody titer values prior to the booster dose of the BNT162b2 vaccine can predict the final antibody response after two doses.

11 Jul 2021

Nanotechnology and the fight against COVID-19

In a review paper published in the open-access MDPI journal Viruses, a team of researchers explored the potential of nanotechnology to alleviate the current and future coronavirus burden. The team focused on its potential role in the detection, diagnosis, protection, and treatment of SARS-CoV-2 infection.

29 Jun 2021

Researchers explore relationship between life expectancy and lifespan equality

Special diets, exercise programs, supplements and vitamins -- everywhere we look there is something supposed to help us live longer. Maybe those work: human average life expectancy has gone from a meager 40-ish years to a whopping 70-something since 1850. Does this mean we are slowing down death?

17 Jun 2021

Could the intranasal route be an alternate avenue of COVID-19 vaccination?

A new study has been published in the journal Vaccines that summarizes the history of vaccines, reviews the current progress in COVID-19 vaccine technology, and discusses the status of intranasal COVID-19 vaccines as a potential pathway to immunization.

8 Jun 2021

Do mixed COVID-19 vaccines provide immunity?

The initial results of the CombivacS trial found that the antibody levels in individuals increased by 150 times when the Pfizer messenger ribonucleic acid (mRNA) vaccine was given after a first dose of the AstraZeneca severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine, with only mild common side effects.

24 May 2021

Oxford-AstraZeneca COVID vaccine induces cell spikes similar to SARS-CoV-2's

Scientists from the University of Oxford and the University of Southampton report in the journal ACS Central Science that cells infected with the ChAdOx1 vaccine produce spike proteins on the cells similar to those produced by natural SARS-CoV-2 infection.

9 Apr 2021

Full assembly of human chromosome 8 reveals novel genes, disease risks

The full assembly of human chromosome 8 is reported this week in Nature. While on the outside this chromosome looks typical, being neither short nor long or distinctive, its DNA content and arrangement are of interest in primate and human evolution, in several immune and developmental disorders, and in chromosome sequencing structure and function generally.

8 Apr 2021

AstraZeneca's COVID-19 vaccine protects against symptomatic disease

Results from a large clinical trial in the United States and South America indicate that AstraZeneca's COVID-19 vaccine, AZD1222, is well-tolerated and protects against symptomatic COVID-19 disease, including severe disease or hospitalization.

22 Mar 2021

ChAdOx1 nCoV-19 offers less protection against South African SARS-CoV-2 variant

The results of a double-blind, randomized, multisite placebo-controlled trial that was conducted in South Africa show that Oxford’s ChAdOx1 nCoV-19 (AZD1222) vaccine has no efficacy against the B.1.351 variant in preventing mild-to-moderate coronavirus disease 2019 (COVID-19), and shows reduced neutralization properties of developed antibodies. The findings are published in the New England Journal of Medicine.

21 Mar 2021

Delayed second dose strategy with mRNA vaccines may reduce COVID-19 mortality, say researchers

An interesting new preprint shows that even if countries are forced to delay the second dose of the current vaccines administered against SARS-CoV-2, to arrest the ongoing COVID-19 pandemic, the cumulative mortality would still fall significantly.

3 Mar 2021

Could measles virus vectors be used for a new COVID-19 vaccine?

A research team at the Institut Pasteur in France describes the successful development of such a vaccine utilizing a measles virus vector.

18 Feb 2021

ZyCoV-D DNA vaccine immunogenic against SARS-CoV-2 in animal models

In the absence of effective therapeutics or preventives, vaccines have become the focus of attention. Though over 170 vaccines are in preclinical and about 60 in clinical development, very few are based on plasmid DNA technology. However, a new preprint research paper posted to the bioRxiv* server reports the immunogenicity of a DNA vaccine candidate.

2 Feb 2021